Association between hsCRP Levels, Glycemic Control and Total Interatrial Conduction Time in Patients with Type 2 Diabetes Mellitus

Isyana Miranti K, Trisulo Wasyanto, Bhisma Murti


Background: Type 2 Diabetes Mellitus (T2DM) represents one of the most important risk factors for atrial fibrillation (AF). Numerous studies have shown that T2DM and poor glycemic control reflected by glycated hemoglobin A1c (HbA1c) levels are independently associated with new onset AF. Recent experimental studies reported that the increased susceptibility to AF in the diabetic patients was presumably due to the slowing of conduction associated with increased interstitial fibrosis. Systemic inflammation cam play role in the development of atrial fibrillation. High-sensitivity C-reactive protein (hsCRP) is an inflammatory biomarker that independently predicts the cardiovascular risk. This study aimed to determine the association between hsCRP level and glycemic control with total interatrial conduction time in T2DM patients.

Subjects and Methods: This was an analytic study with cross-sectional design. A total of samples were 41 patients with T2DM. Peripheral venous blood samples to measure hsCRP and HbA1c were drawn in all study population. The total interatrial conduction time was measured by tissue Doppler echocardiography. Multivariate analysis was performed using multiple regression analysis. P < 0,050 was considered to indicate a statistically significant difference.

Results: The high-sensitivity C-reactive protein level was higher in the T2DM patients with HbA1c≥7% than in the T2DM patients with HbA1c<7%, but not statistically significant (0,44±0,30 vs 0,32±0,22; p = 0,183). The total atrial conduction time was longer in the T2DM patients with HbA1c≥7% than in T2DM patients with HbA1c<7%, but not statistically significant (100,29±28,53 vs 94,88±16,50; p = 0,449). Multiple regression analysis showed that hsCRP levels and glycemic control had significant positive correlation with total interatrial conduction time in T2DM patients (r = 0,51; p = 0,004).

Conclusions: The hsCRP levels and glycemic control were significant positively correlated with total interatrium conduction time in patients with type 2 diabetes.

Keywords: hsCRP, glycemic control, HbA1c, total interatrial conduction time.

Correspondence: Isyana Miranti K. Biomedic, Family Medicine Program, Sebelas Maret University, Surakarta. 

Indonesian Journal of Medicine (2016), 1(1): 58-70

Full Text:



Aksnes TA, Schmieder RE, Kjeldsen SE. (2008). Impact of ne-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol, 101:634-8.

Akyurek O, Sayin T, Dincer I. (2001). Lengthening of intraatrial baffle conduction time in atrial fibrillation and its relation with early recurrence of atrial fibrillation. Jpn Heart J, 42:575-84.

Antoni ML, Bertini M, Atary JZ. (2010). Predictive value of total atrial conduction time estimated with tissue Doppler imaging for the development of new onset atrial fibrillation after acute myocardial infarction. Am J Cardiol, 106:198-203.

Antonio HM. (2006). C-reactive protein and atrial fibrillation. An old marker of a looking for new targets. Rev Esp Cardiol, 59 (2), 94-8.

Andrade J, Khairy P, Dobrev D. (2014). The clinical profile and pathophysiology of atrial fibrillation: Among relationships clinical features, epidemiology, and mechanisms. Circ Res, 114.1453 to 1469.

Bahceci M, Tuzcu A, Ogun C. (2006). Is C-reactive protein serum concentration correlated with HbA1c and insulin resistance in type 2 diabetic men with or without coronary heart disease. J Endocrinol Invest, 28(2):145-150.

Bakirci EM, Demirtas L, Degirmenci H. (2015). Relationship of the total atrial conduction time to subclinical atherosclerosis, inflammation and echocardiographic parameters in Patients with type 2 diabetes mellitus. Clinics, 70(2):73-80.

Bissinger A, Grycewicz T, Grabowicz W. (2011). The effect of diabetic autonomic neuropathy on P wave duration, dispersion and atrial fibrillation. Arch Med Sci, 7(5):806-812.

Boos CJ, Anderson RA, and Lip GY. (2006). Is an inflammatory disorder atrial fibrillation? Eur Heart J, 27 (2), 136-49.

Crandall MA, Horne BD, Day JD. CHADS2 (2009). Atrial fibrillation and risk factors are associated with highly sensitive C reactive protein and Inde-pendently incrementally. Pacing Clin Electrophy¬siol, 32(5):648-52.

Deniz A, Sahiner L, Aytemir K. (2012). Tissue Doppler echocardiography can be a useful technique to Evaluate atrial conduction time. J Cardiol, 19(5): 487 493.

Dilshad AK and Shazia Q. (2009). Evalua-tion of cardiac risk by oxidative stress and inflammatory markers in diabetic Patients. Park J Med Sci, 25, 5.

Dublin S, Glazer NL, Smith N. (2010). Dia-be¬tes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med, 25 8): 853-8.

Engelmann M and Svendsen JH. (2005). Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J, 26, 2083-2092.

Fatemi O, Yuriditsky E, Tsioufis C. Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in Patients with type 2 diabetes mellitus (from the ACCORD study). Am J Cardiol, 114 (8): 1271-1222.

HE Fatma, Erdem A, Ozlu F. (2015). Electrophysiological validation of total atrial conduction time measu¬rement by tissue Doppler echo¬cardiography According to age and sex in healthy adults. J Arrhythmia, 10, 1016.

Friedrichs K, Klinke A, and Baldus S. (2011). Inflammatory pathways under¬lying atrial fibrillation. Trends Mol Med, 17 (10): 556-63.

Fu H, Liu C, Li J. (2013). Impaired atrial electromechanical function and atrial fibrillation promotion in alloxan-induced diabetic rabbits. J Cardiol, 20, 59-67.

Fujiwara M, Nakano Y, Hidaka T. (2014). Prediction of atrial fibrillation after off-pump coronary artery bypass grafting using the total preoperative atrial conduction time determined on tissue Doppler imaging. Circ J, 78, 345-352.

Fuster V, Ryden LE, Cannom DS. (2011). ACCF / AHA guidelines pockets: Mana¬ge¬ment of Patients with atrial fibrillation. Circ J, 123, 1161-1167.

Galea R, Cardilo MT, Caroli A. (2014). Inflammation and C-reactive protein in atrial fibrillation: cause or effect? Tex Heart Inst J, 41 (5):461-8.

Grant RW, Donner TW, Fradkin JE. (2015). Standards of medical care in diabetes Diabetes Care 2015, 38 (Suppl 1), S1-S93.

Gohel MG and Chacko AN. (2013). Serum GGT activity and hsCRP levels in Patients with type 2 diabetes mellitus with good and poor glycemic control: an evidence linking oxidative stress, inflammation and glycemic control. J Diabetes Metab Disord, 12, 56.

Goudis CA, Korantzopoulos P, Ntalas IV. (2015). Diabetes mellitus and atrial fibrillation: Pathophysiological me¬cha¬-nisms and potential therapies upstream. Elsevier, 184: 617-622.

Hatam N, Aljalloud A, Mischke K. (2014). interatrial conduction disturbance in postoperative atrial fibrillation: a comparative study of P-wave dis-persion and Doppler myocardial ima-ging in cardiac surgery. J Cardiotho-rac Surg, 9:114.

Hair JE, Anderson RE, Tatham RL. (1998). Multivariate analysis of data. Upper Saddle River, NJ: Prentice Hall.

Hayden MR, Chowdhury N, Govindarajan G. (2006). Myocardial myocyte remo-deling and fibrosis in the Cardio¬me-tabolic syndrome. J Cardiometab Syndr, 1, 326-33.

Heijman J, Voigt N, Nattel S. (2014). Cellular and molecular electro-physiology of atrial fibrillation ini-tiation, maintenance, and progres-sion. Circ Res, 114, 1483-1499.

Henmi R, Ejima K, Yagishita D. (2015). In-ter-atrial conduction time can Predict new-onset atrial fibrillation after radiofrequency ablation of isolated, typikal atrial flutter. Circ J, 132, A17452.

Huxley R, F Alonso, Lopez. (2012). Type 2 dia¬¬¬betes, glucose homeostasis and in-cident atrial fibrillation: the Athe-rosclerosis Risk in Communities stu-dy. Heart, 98 (2): 133-138.

Igarashi T, Finet JE, Takeuchi A. (2012). Connexin gene transfer preserves conduction velocity and prevents atrial fibrillation. Circulation, 125, 216-225.

Iwasaki Y, Nishida K, Kato T. Pathophysiology. (2011). Atrial fibril¬la-tion: implications for management. Circ J, 124: 2264-74.

CT January, Wann LS, Alpert JS. (2014). AHA/ACC/HRS Guidelines for the Mana¬gement of Patients with atrial fibrillation: executive summary. JACC, 64 (21), 2246-81.

Johansen OE, Brustad E, Enger S. (2008). Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75-year old subjects. Cardiovasc Diabetol, 7, 28.

Kato T, Yamashita T, Sekiguchi A. (2006). What are arrhythmogenic substrates in diabetic rat atria? J Cardiovasc Electrophysiol, 17: 890-4.

Kato T, Yamashita T, Sekiguchi A. (2008). Ages-rage system mediates atrial structural remodeling in the diabetic rat. J Cardiocasc Electrophysiol, 19, 415-20.

Korantzopoulos P, Kolettis TM, Galaris D. (2007). The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol, 115, 135-143.

Lane DA and Lip GY. (2012). Use of the CHA2DS2-Vasc and HAS-BLED sco-res to aid decision making for throm¬-boprophylaxis in nonvalvular atrial fibrillation. Circ J,126,860-865.

Lin Y, Li H, Lan X. (2013). Mechanism of and therapeutic strategy for atrial fi-brillation associated with diabetes mellitus. Scientific World Journal, 11.1-6.

Liu C, Fu H, Li J. Hyperglycemia aggravates (2012). Atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits. Anadolu Kardiyol Derg, 12: 543-550.

Liu C and Li G. (2008). Inflammation: another potential mechanism between diabetes mellitus and atrial fibrillation. Am J Cardiol, 101, 1681-2.

Liu T, Zhao H, Li J. Rosiglitazone. (2014). attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic rabbits. Cardiovasc Ther, 32, 178-83.

Madrid AH. (2006). C-reactive protein and atrial fibrillation: an old marker of a looking for new targets. Rev Esp Cardiol, 59 (2): 94-8.

Maqri CJ and Fava S. (2012). Should Be Considered a diabetes still coronary artery disease equivalent? J Cardio-vasc Med (Hagerstown), 13 (11): 760-5.

KL Merckx, De Vos CB, Palmans A. (2005). Atrial activation time determined by transthoracic Doppler tissue imaging can be used as an estimate of the total duration of atrial electrical activation. J Am Soc Echocardiogr, 18: 940-4.

Mitasikova M, Lin H, Soukup T. (2009). Diabetes and thyroid hormones Affects connexin-43 and PKC-epsilon expression in rat heart atria. Physiol Res, 58: 211-7.

Montori VM. (2008). Should Patients with type 2 diabetes focus on glycemic control to reduce Reviews their cardiovascular risk? Pol Arch Med Wewn, 118 (9): 502-507.

Murphy NF, Simpson CR, Jhund PS. (2007). A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart, 93: 606-12.

Murti B. (2006). The design and sample size for quantitative and qualitative study in the health field. Yogyakarta, Gajah Mada University Press. Issue I: page 23.

Nakou ES, Mavrakis H, and Vardas PE. (2012). Are Diabetic Patients at Increased risk of arrhythmias? Hell J Cardiol, 53: 335-339.

Nattel S, Burstein B, and D. Dobrev, (2008). Atrial remodeling and atrial fibrillation: mechanisms and impli-cations. Circ Arrhythmia Electrophysiol, 1: 62-73.

Nattel S and M. Harada. (2014). Atrial re-mo¬¬deling and atrial fibrillation: recent advances and translational pers-pectives. J Am Coll Cardiol, 63 (22): 2335-2345.

Ostgren CJ, Merlo J, Rastam L. (2006). Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Obese Diabetes Metab, 6: 367-374.

Otake H, Suzuki H, Honda T. (2009). Influences of the autonomic nervous system on atrial arrhythmogenic substrates and the incidence of atrial fibrillation in diabetic heart. Int Heart J, 50:627-41.

Ozaydin M. (2010). Atrial fibrillation and inflammation. World J Cardiol, 2 (8): 243-250.

Ozlu MF, Erdem K, Kiris G. (2013). Predictive value of total atrial conduction time measured with tissue Doppler imaging for postoperative atrial fibrillation after coronary artery bypass surgery. J interv Card Elec¬trophysiol, 37 (1): 27-33.

Quintana DS, Minguez JR, Pizarro G. (2012). Triggers and anatomical sub-strates in the genesis and per-petuation of atrial fibrillation. Curr Car¬diol Rev, 8 (4): 310-326.

Rosenberg MA and Manning WJ. (2012). Diastolic dysfunction and risk of atrial fibrillation: a mechanistic appraisal. Circ J, 126.2353 to 62.

Rudianto A, Lindarto D, Decroli E. (2011). Consensus control and prevention of type 2 diabetes mellitus in Indonesia. Perkeni, 1-66.

Rudolph V, Andrie RRP, Rudolph TK. Myeloperoxidase. (2010). profibrotic acts as a mediator of atrial fibrillation. Nat Med, 16, 470-74.

Saito S, Teshima Y, Fukui A. Glucose fluctuations. (2014). The increase of the incidence of atrial fibrillation in diabetic rats. Cardiovasc Res, 104: 5-14.

Sarinnapakorn V and Wanicagool W. (2013). Association between hsCRP and HbA1c in overweight type 2 diabetic female Patients. J Med Assoc Thai, 96 (3): S54-58.

K. Stadler, (2012). Oxidative stress in diabetes. Adv Exp Med Biol, 771: 272-87.

Sun Y and Hu D. (2009). The link between diabetes and atrial fibrillation: a cause or correlation? J Cardiovasc Dis Res, 1 (1): 10-11.

Timon IM, Collantes CS, AS Galindo. (2014). Type 2 diabetes and cardiovascular disease: all risk factors have the same strength? World J Diabetes, 5 (4): 444-470.

Uijl DW, Gawrysiak M, Tops LF. (2011). The prognostic value of atrial conduction time total estimated with tissue Doppler imaging to Predict the recurrence of atrial fibrillation after radiofrequency catheter ablation. Europace, 13: 1533-1540.

Verrotti A, Prezioso G, Scattoni R. (2014). Autonomic neuropathy in diabetes mellitus. Front Endocrinol (Lausan-ne), 5: 205-211.

Voight N and D. Dobrev. (2012). Cellular and molecular correlates of ectopic activity in Patients with atrial fibrillation. Europace, 14: v97-V105.

Vos CB, Weijs B, Crijns HJ. (2009). Atrial tissue Doppler imaging for prediction of new-onset atrial fibrillation. Heart, 95, 835-840.

Represent R, Voigt N, Kaab S. (2011). Recent advances in the molecular pathophysiology of atrial fibrillation. J Clin Invest, 121 (8): 2955-68.

Watanabe H, Tanabe N, Watanabe T. (2008). Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circ J, 117: 1255-60.

Watanabe M, Yokoshiki H, Mitsuyama H. (2012). Conduction and refractory diabetic disorders in the atrium. Am J Physiol Hear Circ Physiol, 303: 86-95.

Weijs B, de Vos CB, Tieleman RG. (2011). Clinical and echocardiographic correlates of intra-atrial conduction delay. Europace, 13: 1681-1687.

Yazici M, Ozdemir K, Altunkeser BB. (2007). The Effect of Diabetes Mellitus on the P-Wave Dispersion. Circ J, 71: 880-883.

Yap YG. (2009). Inflammation and atrial fibrillation: a cause or para-pheno-menon? Europace, 11, 980-1.

Yuasa T and Imoto Y. (2016). Usefulness of tissue doppler imaging-derived atrial conduction time for prediction of atrial fibrillation. Circ J, 80: 58-59.

Yuan G, Zhou L, Tang J. (2006). Serum equally elevated CRP levels in newly Diag¬no¬sed with type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. Diabetes Res Clin Pract, 72:244-50.

Yuniadi Y, Tondas AE, Hanafy DA. (2014). Guidelines for governance of atrial fibrillation. Jakarta, Centra Commu-nications. Issue I: it 1-6.

Zhang Q, Liu T, Chee YN. (2014). Diabetes mellitus and atrial remodeling: upstream mechanisms and potential therapies. Cardiovasc Ther, 13: 233-241.


  • There are currently no refbacks.